Project cooperationUpdated on 8 September 2025
Engineered EV Platform: Multivalent Infectious-Disease Vaccines & application for Drug Delivery System (DDS)(改変型EVによる多価感染症ワクチンとDDSへの展開)
About
**EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.
**Our engineered EV platform enables a multivalent intranasal vaccine (Influenza A/B + SARS-CoV-2).
Design: multi-antigen loading with proprietary antigen shielding allowing adult intranasal use.
Efficacy: rapid (~Day 8) induction with >6-month durability; variant-resilient and boostable.
Safety/UX: low reactogenicity, non-invasive/painless.
Stability: refrigerated and room-temperature storage.
Cost: projected below existing vaccines.
IP: strong US–Japan patent estate supporting exclusivity.
Plan: US IND 2029 → PoC 2031; open to global partnering/out-licensing.
Platform extensions: (1) Oncology EV vaccine, (2) CNS-targeted nucleic-acid EV (DDS), (3) immune-tolerance EV; plus efficient protein loading and advanced CMC/QC markers for scalable, consistent development.
Stage
- Planning
Type
- Research
- Technical
- Financing
Attached files
Organisation
Similar opportunities
Project cooperation
Atopic Dermatitis Therapy Using MSC-Derived Extracellular Vesicles
- Planning
- Research
- Technical
- Financing
Project cooperation
Therapeutic for lung injury (ARDS, IPF) using MSC-derived Extracellular Vesicles(
- Planning
- Research
- Technical
- Financing